FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
74.37 USD
1.35 (1.82%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
-
-36.34
-10.71
-11.56
-0.61
-14.81
-14.81
-14.81
-14.81
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
4.87
1.13
-8.47
5.54
4.52
1.52
1.52
1.52
1.52
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
-1.22
-2.06
-1.76
-1.7
-1.71
-1.69
-1.69
-1.69
-1.69
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
1.91
32.56M
10.51
10.51
366.79M
62.19M
428.98M
85.5
14.5
9.25
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
9.25
9.25
9.25
9.25
9.25
-1.86M
-1.45M
-1.13M
-881.81k
-687.64k
-6.01M
9.25
-1.09M
-15.06M
-9.67M
-15.68M
325.52M
-341.2M
32.56M
-10.48
-10.48 1.182%